Synopsys Signs Off on Every AI Chip. The Market Still Pays More for Cadence.

An AI chip is finished long before it exists. Months of work happen in software first: circuits placed, timing checked, heat mapped, design signed off. Almost all of it runs on Synopsys (NASDAQ: SNPS).

Synopsys does not make chips. It sells the software every chip is designed in before a fab touches silicon, plus the pre-built circuit blocks customers license instead of building. It is the building department for silicon: nothing gets poured until the drawings clear review.

That makes Synopsys the permit office rather than a contractor. It gets paid on design activity, not on how many chips ship, and the fee scales with complexity rather than with the customer's success. Every new node and multi-die stack runs through that review.

AI is why the chip-start count keeps climbing. Every hyperscaler building its own accelerator, package stacking logic beside memory, adds verification and interface work that lands in these tools. Die-to-die IP is on pace to double this year, past 100 cumulative design wins.

One year ago Synopsys closed its Ansys acquisition, buying the thermal and structural simulation that multi-die chips now need. The first fused products shipped in June, with NVIDIA, Cisco, MediaTek and Samsung Foundry validating up to ten times faster design closure. Revenue starts in fiscal 2027.

The quieter shift is how Synopsys bills. Its standards IP business sells one-time licenses; the new custom-silicon arm wants a royalty on top. “This is our Factory 2 model for customized IP. It moves us up the value chain from licensing alone to licensing plus royalties,” says Sassine Ghazi, president and CEO.

Now the hard question. If autonomous agents do the engineering, do the seats disappear? Synopsys's answer: “as these agents take on more engineering work, they orchestrate our underlying EDA tools at a significantly higher rate,” says Ghazi.

That claim rests on 30-plus customer engagements and no pricing proof yet.

So what re-rates this equity? The license-to-royalty mix has to appear in reported revenue rather than on a slide. Agentic tools have to bill as incremental demand rather than a cheaper substitute for seats. The Ansys cost synergies also have to keep landing early.

The market is not paying for any of that yet. The backlog sits at $10.9 billion. The shares have lagged badly this year and sit well below their high, while Cadence commands a richer forward multiple on smaller revenue.

NVIDIA bought $2 billion of this stock last December and is under water on it.

Now the short case, which is not weak. China was 11.5% of revenue last year and fell hard on an ex-Ansys basis. Guidance assumes no further changes to export controls, after guidance was pulled once in 2025. Synopsys has also disclosed administrative subpoenas from the Bureau of Industry and Security.

Concentration compounds it. One customer and its subsidiaries were 12.6% of a prior year's revenue, and the annual report admits a major foundry customer hurt fiscal 2025. Design IP, the segment most exposed to buyers building their own interface blocks, fell about 8% last year; the bounce since is flattered by a divestiture.

The Ansys bill keeps arriving. Restructuring charges were revised up to $425 million to $500 million alongside a 10% workforce cut. Quarterly intangible amortization runs near $402 million, and tangible book value is negative $7.1 billion.

The existential worry was put to the CEO directly. Ghazi told analysts an AI-native flow that bypasses commercial tools is the opposite of a threat, because the models keep learning. His own marketing promises 40% faster debug and 50 times faster RTL verification, the engineer hours a seat license is priced on.

If agentic bookings land as a discount to seat revenue instead of a new line, the bears are right.

What we're watching is eight days out. At its Investor Day on September 30 in New York, management has promised to model what it has only described. That covers how agentic tools get priced, what a Factory 2 royalty earns, the fiscal 2027 lift from the joint Ansys products, and the $400 million revenue-synergy target.

The number to hunt for is the long-term IP growth guide, which has sat at mid-teens for two years. If Factory 2 royalties push that higher, the mix shift is real.

Anyone who has priced a kitchen renovation knows this part. The quote lands before the demolition, it climbs once the wall comes down, and it is still the cheapest check in the project.

Synopsys never gets paid for a chip. It gets paid for the certainty that the chip can be built, and it collects that fee before anyone breaks ground.

Disclosure: The Signal holds no position in SNPS. Positions may change. This is not financial advice.